on behalf of the Pompe ADVANCE Study Consortium Purpose: To characterize clinical characteristics and genotypes of patients in the ADVANCE study of 4000 L-scale alglucosidase alfa (NCT01526785), the largest prospective United States Pompe disease cohort to date.
INTRODUCTION
Pompe disease or glycogen storage disease type II (OMIM 232300) is a rare, autosomal recessive disorder of glycogen metabolism caused by deficiency of the glycogen-degrading lysosomal enzyme acid α-glucosidase (GAA, EC 3.2.1.20), 1 leading to multisystemic lysosomal glycogen accumulation. Clinical symptoms primarily reflect cardiac, respiratory, skeletal, and smooth muscle involvement. 1 The disease spectrum ranges from infantile-onset Pompe disease (IOPD; symptom onset <12 months of age with cardiomyopathy 2 ) to the more slowly progressive late-onset Pompe disease (LOPD; symptom onset <12 months of age without cardiomyopathy or onset ≥12 months of age 2 ). Prognosis for IOPD patients depends on several factors, including not only GAA genotypes (and any resulting residual functional GAA activity) but also cross-reactive immunologic material (CRIM) status. 3 CRIM-negative patients harbor GAA variants (nonsense, insertion, deletion, or indel) abrogating native GAA protein synthesis or prematurely truncating the protein product, which is targeted for ubiquitination and protealyzed. 4 In contrast, CRIM-positive patients produce some immunologically recognizable GAA protein. CRIM status can usually be predicted from genotypes. 3 The degree of Pompe disease progression at treatment initiation strongly affects prognosis. Diagnostic delays, particularly in IOPD, lead to worse outcomes. 2 Alglucosidase alfa (recombinant human GAA [rhGAA]) received regulatory approval in 2006 in the United States and Europe as the first and only disease-specific treatment for Pompe disease. The studies supporting initial approval demonstrated increased overall and ventilator-free survival and cardiac, respiratory, and motor improvement in IOPD patients receiving alglucosidase alfa produced at a 160 L pilot scale (160 L rhGAA). 5, 6 Alglucosidase alfa manufactured at a larger scale (Lumizyme®) was evaluated in LOPD patients ≥8 years of age without cardiomyopathy, 7 receiving US approval in 2010 initially for that population. The ADVANCE study (NCT01526785) evaluated comparability of 4000 L rhGAA safety and efficacy in pediatric 160 L rhGAA-experienced patients with Pompe disease, irrespective of cardiac phenotype. 8 Its safety data supported the US label expansion of Lumizyme® (alglucosidase alfa) in 2014 to include all patients with Pompe disease.
The ADVANCE study was open to US patients with a confirmed Pompe disease diagnosis (deficient endogenous GAA activity and/or GAA genotype) ≥1 year of age at study entry who were receiving 160 L rhGAA at enrollment. This contemporaneous, prospective cohort of 113 patients provides a unique, one-time opportunity to understand the genotypic and phenotypic spectrum of Pompe disease in the United States via systematic clinical histories and assessments, to compare variant types found in IOPD and LOPD, and to ascertain novel Pompe disease variants within the population.
MATERIALS AND METHODS

Design and ethics
This prospective, open-label, single-arm study was conducted at 52 centers in 30 states plus Washington, DC (29 March 2012 -29 December 2014 . Parents/guardians (or patients if ≥18 years old) gave written informed consent; children assented whenever possible. Western Institutional Review Board (IRB; Puyallup, WA) or local sites' IRBs (online appendix) gave ethical approval; Good Clinical Practice, the Declaration of Helsinki 1964 and applicable amendments 9 , and all applicable laws, regulations, and guidelines were followed.
Patients
Patients aged ≥1 year with enzymatically and/or molecularly confirmed Pompe disease previously treated with 160 L rhGAA were eligible. Patients enrolled in other studies or receiving other investigational treatments within 3 months before screening, unlikely to survive through 52 weeks of treatment, or unable to comply with study procedures were excluded. Negative pregnancy tests were required for postmenarchal female patients.
Assessments
GAA genotypes (reference sequence NM_000152) were determined at or before screening (five enzymatically diagnosed patients lacked genetic data). Prior GAA genotypes determined before study entry were used if provided by a certified laboratory with guardians'/patients' written informed consent to share with the site. In the case of missing genotype information, informed consent was obtained to conduct nextgeneration sequencing (NGS) of the GAA gene by LabCorp (www.LabCorp.com) (GAA Inheritest®, 451910) and share the data with the site. Prediction of IOPD patients' CRIM status relied on historical data from identical GAA variants identified in other patients. Patients whose GAA variants precluded GAA protein production were considered CRIMnegative. 3 Reported variants used in CRIM prediction were presumed to be (1) those causing Pompe disease (supported by database or literature reports of pathogenicity and/or by GAA enzyme activity levels), i.e., patients did not have another, unidentified pathogenic variant; and (2) in trans (reported in-cis combinations were confirmed by parental testing).
Left ventricular mass (LVM) z-scores were determined via locally read and centrally reviewed M-mode echocardiography. Standard 12-lead electrocardiography, locally read and reviewed by a central cardiologist blinded to patient and study timepoint, ascertained left or right ventricular hypertrophy criteria and heart rhythm. Congestive heart failure (CHF) was determined clinically, with New York Heart Association (NYHA) staging.
Invasive or noninvasive ventilator dependence was scored as of the first ventilation date not followed by 14 consecutive ventilator-independent days. For testable ventilator-free patients, seated (upright) forced vital capacity (FVC) % predicted was determined following American Thoracic Society guidelines.
Motor skills were assessed via Gross Motor Function Measure, 88 items (GMFM-88), which has precedent (though not formal validation) for use in Pompe disease. 10, 11 Motor function levels and histories were assessed at study entry only, classifying patients as walkers, supported walkers, supported standers, sitters, or restricted antigravity movement. Questions on motor decline during the 2 months before enrollment were specific to functional level and age group (<2 or ≥2 years of age).
Medical histories were collected emphasizing systems affected by Pompe disease. Biochemical testing included serum creatine kinase, brain natriuretic peptide, and aspartate and alanine aminotransferases.
Analyses
Demographic, clinical, and genetic characteristics are reported as summary statistics overall and (post hoc) for IOPD and LOPD subsets. IOPD patients were those with symptom onset by 12 months of age and evidence of cardiac involvement (cardiomegaly, cardiomyopathy, or hypertrophies), potentially including some patients with less severe cardiac phenotypes.
RESULTS
Demographics, clinical characteristics, and medical histories
One hundred thirteen patients were enrolled (aged 1.0-18.7 years at consent; Table 1 ). The CONSORT diagram was published previously. 8 The one excluded patient had previously received commercial 4000 L rhGAA. At consent, ages of IOPD patients were 1.0-15.5 years (mean ± SD, 4.4 ± 3.52 years; median, 3.4 years); those of LOPD patients were 1.1-18.7 years (mean ± SD, 6.0 ± 4.19 years; median, 6.1 years). IOPD was defined as symptom onset at <12 months of age with cardiac involvement, and LOPD as symptom onset either at <12 months of age without cardiac involvement or at ≥12 months of age.
2 Eighty-seven patients had IOPD and 26 had LOPD (20 without and 6 with cardiac involvement).
Of the 87 IOPD patients, 70 had symptom onsets and 160 L rhGAA initiations before 12 months of age. Seventeen more met IOPD criteria but had survived >12 months before 160 L rhGAA initiation and could include advanced and less severe IOPD cases. Their reported age range at symptom onset was 0-8.8 months, at diagnosis 40 days-5.9 years. Reported 160 L rhGAA initiations were at 1.0 to~11 years, and ages at ADVANCE enrollment 2.1-15.5 years. Two of these had received other investigational enzyme therapies before 160 L initiation (one received Synpac rhGAA starting at~2 years of age, then 160 L rhGAA at~11 years of age; the other received expanded-access rhGAA starting at~6.9 years of age, then 160 L rhGAA at~7.9 years of age). Further details are in ADVANCE efficacy publication supplementary materials. 8 All IOPD patients were analyzed together.
LOPD symptom onset ranged from 1.1 to 5 years in the 6 patients with cardiomyopathy/cardiomegaly, versus birth-8.9 years in the other 20 patients. Proportionately more LOPD than IOPD patients were Caucasian (88% vs. 55%), male (73% vs. 47%), ventilator-free (69% vs. 59%), and walked independently (27% vs. 18%) or with assistance (35% vs. 18%). Only 8% of LOPD patients, but 28% of IOPD patients, had restricted antigravity movement at enrollment ( Table 1) .
Thirty-two patients were invasive ventilator-dependent (26 IOPD, 6 LOPD) for a median of 3.9 years (mean ± SD, 4.8 ± 4.14 years; range, 0.1-17.0 years). Eleven further patients were noninvasive ventilator-dependent (9 IOPD, 2 LOPD). Seventy-five (66%) patients had histories of pneumonia (61/ 87 [70%] with IOPD and 14/26 [54%] with LOPD).
Motor symptomatology at study entry ( Table 2 ) included lower extremity weakness in 101 (89%) patients, upper extremity weakness in 94 (83%), and motor milestone regression in 45 (40%). At screening, 48 (42%) patients were ambulatory (independently or device-assisted); 65 (58%) were nonambulatory at screening, 11 of whom had ever walked. In all, 54 (48%) used ambulatory or mobility devices. Most never-ambulatory patients had later 160 L initiations (35 (6) 6 (7) 1 ( (10) 10 (12) 1 (4) Using ambulatory devices at enrollment, n (%) patients initiated at >6 months of age versus 10 initiated at 3-6 months and 9 initiated at 0-3 months).
Sleep disturbance/apnea, failure to thrive, gastric reflux, chronic otitis media, and hearing loss appeared more prevalent in IOPD than LOPD ( Table 2) . Conductive hearing loss affected 13/87 (15%) IOPD and 2/26 (8%) LOPD patients; sensorineural hearing loss affected 6/87 (7%) IOPD and 1/26 (4%) LOPD patients.
Family histories
Nineteen (17%) patients had a sibling with Pompe disease. Five phenotypically concordant sibling pairs (three pairs with IOPD and two pairs with LOPD) jointly participated in ADVANCE; 8 patients had nonparticipating affected siblings, and 1 LOPD patient without genetic data had an affected sibling. One IOPD patient's mother had an LOPD genotype (11 patients' parents were tested).
GAA pathogenic variants
In the full analysis set (n = 113), 108 (96%) patients had genetic data comprising 215 GAA pathogenic variants (220 including in-cis combinations) ( Fig. 1; Supplementary  Table S1 ). Four IOPD patients and one LOPD patient had missing genotypes. Two patients had three variants, two in cis and one in trans, and one patient had four variants: two in-cis combinations in trans to each other. The three most frequent Table 2 Pompe disease history at study entry (full analysis set and disease state subsets) with an incompletely reported genotype or for four IOPD patients without genotypes.
Shared genotypes
Supplementary Table S3 shows all reported genotypes in IOPD and LOPD, their shared or unshared status within ADVANCE, and whether patients had affected siblings. No complete genotypes were shared between ADVANCE IOPD and LOPD patients.
In IOPD, two siblings shared splice variant c.−32−17_−32 −10del8ins30 31 and missense variant c.1979G>A. 32 Two other siblings shared nonsense c.525delT 13 and missense c.1448G>T. 23 A third sibling pair shared splice c.546+2_ +5delTGGG 3 and duplication c.1650dupG. 3 Three unrelated patients were homozygous for missense variant c.2297A>C.
14 Homozygous missense c.1843G>A
28 was shared by two unrelated patients, as was homozygous missense c.1844G>A. 18 Seven unrelated patients shared genotypes containing nonsense variant c.2560C>T
12
: three were homozygous (all African Americans). Two unrelated African American patients were compound heterozygous with c.1447G>A as the second pathogenic variant. 23 One Caucasian and one African American were compound heterozygous with c.525delT as the second pathogenic variant. 13 In LOPD, twins with cardiac involvement shared c.1210G>A 16 and c.1445C>T. 23 Two siblings without cardiac involvement shared c.-32-13T>G 15 and c.258dupC. 27 Three unrelated patients shared c.-32-13T>G 15 and c.525delT. 13 
Cardiac history and function
All patients with IOPD (by definition) and 6 of 26 with LOPD had cardiac involvement. LVM z-scores (M-mode) at entry ranged from −4.0 to 10.3 (mean ± SD, −0.1 ± 2.63) [n = 85]) overall. Cardiac conditions reported in cardiovascular history at study entry or ascertained by baseline assessment are described below.
IOPD
A history of cardiomegaly was reported in 72/87 (83%) IOPD patients at study entry (Supplementary Table S5 lists all IOPD patients' cardiac symptoms and their onset ages). LVM z-scores at study entry ranged from −3.8 to 10.3 (mean ± SD, 0.4 ± 2.80 [n = 62 evaluable]) in IOPD. Thirteen (15%) had cardiomyopathy or hypertrophy without reported cardiomegaly. One patient (1%) had interventricular septal hypokinesis alone reported at study entry, and one (1%) had dysrhythmia alone at diagnosis. Many patients' histories of CHF or dysrhythmias coexisted with cardiomegaly or cardiomyopathy: 26 (30%) IOPD patients had CHF. Other heart conditions affected 26 (30%) IOPD patients. Of these, 8 had arrhythmia (unspecified), 7 had Wolff-Parkinson-White (WPW) syndrome (3 without and 4 with supraventricular tachycardia [SVT]), 6 had SVT without WPW, 1 had sinus tachycardia, and 4 had unspecified tachycardia. SVT predominantly affected patients with deletions or nonsense variants. Table S4 ). Two of six also had CHF; one had SVT. One patient had SVT and WPW without cardiomegaly, cardiomyopathy, or CHF. LVM z-scores for LOPD overall were −4.0 to 1.0 (mean ± SD, −1.5 ± 1.42 [n = 23]), and among the six cardiac-affected LOPD patients, −1.58 to 0.66.
LOPD
Six of 26 (23%) LOPD patients had cardiac involvement (Supplementary
Respiratory function
Baseline seated FVC mean ± SD was 66.6 ± 29.6% predicted in 24 evaluable patients (15 IOPD, 55.9 ± 26.7% predicted; 9 LOPD, 84.4 ± 26.3% predicted).
Motor function GMFM-88 total % scores were available for 108 patients. Means, medians, and ranges overall and for IOPD and LOPD, along with Pompe motor function categories at study entry, appear in Table 1 . Motor decline in the 2 pre-enrollment months was noted in 7 patients <2 years old (5 IOPD, 2 LOPD) and 30 patients ≥2 years old (24 IOPD, 6 LOPD). 
DISCUSSION
The ADVANCE baseline cohort provides the largest multiethnic, systematically assessed data set to connect Pompe genotypes, phenotypes, and clinical manifestations in the United States.
The phenotypically unrestricted cohort spanned the clinical spectrum of Pompe disease, including IOPD and LOPD. The minority (17%) of CRIM-negative IOPD patients may reflect fewer surviving to join ADVANCE. Diagnostic and prestudy 160 L rhGAA initiation ages reflect that some patients had delayed diagnosis and/or extended disease evolution before initiation of treatment.
Cardiac involvement in LOPD is occasionally reported. 35 Six patients who had initial symptom onsets at >1 year (thus LOPD) had cardiac involvement, which often presented later than first symptoms at ages from 1.03 years to >5 years (Supplementary Table S4 ). All six lacked the common Caucasian LOPD splice variant c.−32−13T>G (IVS1), which typically does not confer cardiac involvement. 36 These patients had other symptoms (e.g., gastric reflux, sleep apnea, hearing loss) suggesting more severe disease. 37 Compound heterozygosity for attenuated variants among these patients suggests that severe variants in trans can lead to a more severe LOPD phenotype or one intermediate between IOPD and LOPD. For example, exon 18 deletions conferred a cardiac LOPD phenotype when combined with attenuated variants. Participants who developed cardiomyopathy beyond 1 year of age (≤5.3 years in LOPD), especially those without the common IVS1 splice site variant, illustrate the need for continued cardiac vigilance with increasing age in LOPD. 35 Mean LVM z-score in IOPD was below hypertrophic cardiomyopathy levels at study entry, but SDs and maxima suggest persistent hypertrophy at study entry in some patients. This could reflect short treatment duration before study entry, CRIM-negative status, high-sustained antibody titers at entry, or echocardiographic variability. Overall LOPD mean and maximum LVM z-scores were not hypertrophic, and the minimum was below normal. LOPD patients with cardiac histories nevertheless had LVM z-scores within normal range at study entry. Potential challenges in echocardiographic data acquisition suggest caution in interpreting score extremes. Diverse prestudy 160 L rhGAA treatment durations likely increased heterogeneity.
Cardiac rhythm abnormalities among ADVANCE IOPD patients included supraventricular tachycardia, short PR interval, and ST abnormalities, all previously reported in treated IOPD. 37 Motor histories, including loss of prior ambulation, motor milestone regression, or other motor decline reported during the two prestudy months, demonstrated the tendency of motor gains on alglucosidase alfa to regress with increasing age. 37 Of note, 34 never-ambulatory patients were >2 years old at enrollment (28 IOPD, 6 LOPD), beyond the normal developmental window for walking. This could be related to advanced stage at 160 L initiation.
Invasive or noninvasive ventilation in 38% of ADVANCE patients indicates respiratory muscle weakness persisting at study entry. Among the 24 testable patients, mean FVC % predicted was higher in LOPD than IOPD, reflecting less severe respiratory muscle involvement. One IOPD patient and one LOPD patient had experienced 5-10 pneumonia episodes in the prior year; none experienced >10. Overall pneumonia rate (66%) exceeded that expected for age. 38 The small number of patients who were both ventilator-free and old enough for reliable FVC measurement is a limitation.
Growth parameter z-scores (Table 1) were within 2 SDs of age norms, as published 37 for long-term IOPD survivors on 160 L rhGAA. However, z-score minima below -2 indicated residual growth deficits in some ADVANCE participants, possibly related to motor difficulties with feeding. Swallowing impairment and/or gastroesophageal reflux, known in treated IOPD 37 and LOPD, 33 were also prevalent in ADVANCE. Nearly 52% of participants with IOPD and 27% with LOPD required tube feeding.
ADVANCE findings corroborate multisystem involvements in long-term treated Pompe disease, e.g., hearing loss in treated IOPD 37 and LOPD. 39 Histories collected at ADVANCE entry showed conductive loss in 15% of IOPD and 8% of LOPD patients. Sensorineural loss affected 7% of IOPD and 4% of LOPD patients. In a prior audiometric study, 39 sensorineural hearing loss affected 10/11 (91%) IOPD patients but no LOPD patients, and conductive loss affected 1/13 (8%) LOPD patients.
Apparently unreported GAA variants found in ADVANCE include three in-cis combinations, two splice variants (one in both IOPD and LOPD, the other in IOPD), and one missense variant in IOPD.
The IVS1 splice variant, c.−32−13T>G, is common in Caucasians with LOPD. None of the 12/26 LOPD patients (46%) in ADVANCE with this variant had cardiac involvement. Conversely, none of six LOPD patients with cardiac involvement had this variant. ADVANCE corroborates Herbert et al., who found occasional arrhythmia and valvular abnormalities but no hypertrophic cardiomyopathy among <18-year-olds with the common c.−32−13T>G variant. 36 The one c.−32−13T>G homozygote in ADVANCE had symptom onset at a typical clinically diagnosed age (8.92 years). In contrast, four published newborn-screened c.−32 −13T>G homozygotes had subtle motor signs by 6 months of age. 33 In ADVANCE, exon 18 deletions co-occurred with cardiac involvement in five IOPD and two of three LOPD patients bearing them. While exon 18 deletions are associated with IOPD and occur compound heterozygously with less severe variants in LOPD, 20 their relationship to LOPD cardiac involvement needs further study.
Of the 17 IOPD patients starting 160 L rhGAA at >12 months of age (bold type in Supplementary Table S5 ), 14 were CRIM-positive, 2 CRIM-negative, and 1 had missing data. The predominantly CRIM-positive status of IOPD patients surviving to treatment initiations at >1 year of age (some of whose cardiac involvement occurred later than initial symptom onset) reinforces a spectrum of involvement in IOPD.
ADVANCE contains a diverse population. No complete genotypes were shared between participants with IOPD and LOPD, reinforcing the role of variant types and combinations in determining disease course.
Limitations of ADVANCE baseline data include approximations in onset, diagnosis or 160 L initiation ages reported historically, particularly for adolescent patients at study entry. Also, retrospective application of IOPD and LOPD definitions revealed some patients as intermediate on the disease spectrum (less severe IOPD with 160 L initiations >12 months of age; cardiac-involved LOPD). Highly variable 160 L rhGAA treatment durations, possible prestudy regimen variations, and incomplete echocardiographic and pulmonary data are other limitations. The strength of the ADVANCE study is that it represents the largest and most inclusive Pompe disease cohort with systematic and comprehensive assessments in the United States. ADVANCE has expanded the number of GAA pathogenic variants observed and has helped further characterize the phenotypic spectrum of Pompe disease.
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